- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Wanbury ropes in Prakash Venkatraman as President of API business
![Wanbury ropes in Prakash Venkatraman as President of API business Wanbury ropes in Prakash Venkatraman as President of API business](https://medicaldialogues.in/h-upload/2024/08/16/750x450_248114-prakash-venkatraman-50.webp)
Mumbai: Wanbury Limited has announced the appointment of Prakash Venkatraman as President of the API business. With a stellar career spanning over three decades, Venkatraman has a wealth of experience in API operations, P&L management, and business strategy.
Venkatraman most recently served as Senior Vice President of the API business at Shilpa Pharma Lifesciences for over 3 years. In this role, he spearheaded the API division, driving growth and delivering on revenue and EBITDA targets.
Previously, Venkatraman led Global Sales and Business Development for Sun Pharma's API division, a $175 million business, as Senior Vice President for over 2 years. Venkatraman spent 8 years at Jubilant Life Sciences as Senior Vice President of the API business. He led a $105 million division, establishing Jubilant as a global leader in specific molecules and expanding capacity to meet surging demand.
Venkatraman's career also includes senior leadership roles at Wockhardt, Ranbaxy, and Kopran, where he consistently delivered on organizational objectives.
Venkatraman holds a Bachelor's degree in Chemical Engineering and a Master's degree in Management Studies from Mumbai University.
Read also: Shilpa Medicare successfully completes Phase 1 clinical trial for Recombinant Human Albumin 20%
Wanbury Limited has a presence in API global market and domestic branded Formulation. Wanbury strength lies in Active Pharmaceutical Ingredient (API) Sales & Marketing in over 50 countries and Pan-India Formulation presence. The Company has a basket of over 13 API products. It has the larger customer base in Europe & US for Tramadol & Setraline (API).The Company has two US-FDA approved multi-product API facilities and one plant under operation for semi-regulated markets. It has pan-India presence in ethical formulations with a portfolio of close to 70 brands.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751